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Impairment of health after overcoming the acute phase of COVID-19 is being observed more and more frequently.
Here different symptoms of neurological and/or cardiological origin have been reported. With symptoms, which
are very similar to the ones reported but are not caused by SARS-CoV-2, the occurrence of functionally active
autoantibodies (fAABs) targeting G-protein coupled receptors (GPCR-fAABs) has been discussed to be involved.
We, therefore investigated, whether GPCR-fAABs are detectable in 31 patients suffering from different Long-
COVID-19 symptoms after recovery from the acute phase of the disease.
The spectrum of symptoms was mostly of neurological origin (29/31 patients), including post-COVID-19 fa-
tigue, alopecia, attention deficit, tremor and others. Combined neurological and cardiovascular disorders were
reported in 17 of the 31 patients. Two recovered COVID-19 patients were free of follow-up symptoms. All 31
former COVID-19 patients had between 2 and 7 different GPCR-fAABs that acted as receptor agonists. Some of
those GPCR-fAABs activate their target receptors which cause a positive chronotropic effect in neonatal rat car-
diomyocytes, the read-out in the test system for their detection (bioassay for GPCR-fAAB detection). Other
GPCR-fAABs, in opposite, cause a negative chronotropic effect on those cells. The positive chronotropic
GPCR-fAABs identified in the blood of Long-COVID patients targeted the β2-adrenoceptor (β2-fAAB), the α1-
adrenoceptor (α1-fAAB), the angiotensin II AT1-receptor (AT1-fAAB), and the nociceptin—like opioid receptor
(NOC-fAAB). The negative chronotropic GPCR-fAABs identified targeted the muscarinic M2-receptor (M2-fAAB),
the MAS-receptor (MAS-fAAB), and the ETA-receptor (ETA-fAAB). It was analysed which of the extracellular
receptor loops was targeted by the autoantibodies.1. Introduction
The pandemic COVID-19 viral infection is often associated with se-
vere respiratory and neurological complications, cardiovascular prob-
lems, microvascular and endothelial disorders, and gastrointestinal
diseases. Additionally, these symptoms are often observed in patients
who have already recovered from the disease and had negative follow-up
coronavirus tests. In their Italian study, Carfi et al. [1] indicated that onlyACE2, Angiotensin-converting en
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evier B.V. This is an open access12.6% of investigated patients did not develop any persistent symptoms
after recovering from COVID-19. Most of the symptomatic post-infection
COVID-19 patients suffered from neurological disorders, such as chronic
fatigue syndrome, postural orthostatic tachycardia syndrome (PoTS) and
dysautonomia [1]. However, other neurological diseases, such as trans-
verse myelitis, acute necrotising myelitis, Guillain-Barre syndrome and
others, have also been reported in several recent case reports on patients
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that showed only 22% of their investigated COVID-19 patients stayed
free of post-disease symptoms [10].
Besides neurological manifestations, patients who recovered from
COVID-19 also often developed cardiovascular implications [11]. The
most prevalent abnormalities observed included myocardial inflamma-
tion, arrhythmia, tachycardia, bradycardia, and atrioventricular (AV)
block [10,12–18]. In a large multi-centre study, including the intensive
care units of 68 geographically diverse hospitals across the United States,
Hayek and co-workers investigated 5019 critically ill COVID-19 patients.
They observed that of these 5019 patients, 14% (701/5019) had an
in-hospital cardiac arrest which was associated with poor survival,
particularly among older patients [19].
Several authors assumed that autoimmune processes, involving the
formation of autoantibodies, may be involved in the pathogenesis [20]
and development of a post-COVID-19 syndrome [20–22]. In an initial
study by Zhou et al. [20], 21 patients critically ill with COVID-19 were
investigated for the presence of autoantibodies. It was found that 20%
had anti-52 kDa SSA/Ro antibodies (autoantibodies against extractable
nuclear antigens), 25% had anti-60 kDa SSA/Ro antibodies and 50% had
anti-nuclear antibodies.
Other autoantibodies acting as drivers of the disease have also been
reported. It was recently shown by Bastard et al. that over 10% of their
investigated COVID-19 patients with a life-threatening pneumonia con-
dition (n ¼ 987) presented with neutralizing autoantibodies against
interferon-ω (IFN-ω, n ¼ 13), the 13 types of IFN-α (n ¼ 36), or against
both (n¼ 52). A few of their patients also showed autoantibodies against
the other three type I IFNs. In contrast, the authors did not see any of
these autoantibodies in 663 patients with asymptomatic or mild SARS-
CoV-2 infection and they were only present in 4 of 1227 healthy sub-
jects included for comparison [23]. Bastard et al. concluded from their
data that the pre-existence of neutralizing anti-type I IFN autoantibodies
was the cause of a critical condition, rather than it being the consequence
of the infection [23].
Novelli et al. concluded from their comprehensive systematic review
about chronic inflammatory and autoimmune diseases onset during
COVID-19 that “it is likely than the autoimmune manifestations described in
COVID-19 represent more the results of the inflammatory cascade and the
immune activation triggered by the virus rather than a direct effect of the virus
per se” [24].
In another study, Lyons-Weiler compared immunogenic peptides of
SARS-CoV-2 with sequences of human proteins and found a high number
of matching homologous sequences [25]. This would explain the high
rate of persisting autoreactivity after SARS-CoV-2 infection. Kreye et al.
examined neutralizing anti-SARS antibodies of isolated B-cell clones and
observed that some showed “self-reactivity” while others were virus
neutralizing only without showing any self-reactivity [26]. The possible
impact of autoantibodies on the pathogenesis has most recently been
discussed by Khamsi [27].
It is a proven fact that autoimmune processes and the formation of
functional autoantibodies (fAABs) directed against G-protein coupled
receptors (GPCR) play a role in the development of neurological [28–30]
and cardiovascular symptoms [31]. Therefore, in this present study, it
was tested if such GPCR-fAABs might also be associated with the devel-
opment of corresponding post-COVID-19 symptoms. We investigated
virus-free sera from 31 recovered COVID-19 patients with respect to the
occurrence of GPCR-fAABs.
2. Material and methods
2.1. Patient sera
Sera were obtained from 31 patients, 29 who were still suffering from
post-COVID-19 symptoms, after recovery from acute disease and 2 pa-
tients who were symptom-free (all positive tested by PCR). All patients
signed a written informed consent form which included giving2
permission to include the anonymised clinical data in a scientific publi-
cation, in agreement with the Declaration of Helsinki. Using the RedCap
project for data collection and management [32] with the permission
from the ethics commission (no: 295-20 B), 6 of the sera were recruited at
the University of Erlangen.
2.2. Serum
As a safety-precaution, the COVID-19 patient sera were heat inacti-
vated for 30 min at 56 C before use. Afterwards, 0.4 mL of the samples
were dialysed against 1 L of dialysing buffer (0.15 M NaCl, 10 mM
phosphate buffer, pH 7.4; Membra-Cel MD 44, 14 kDa, Serva) for 24 h to
remove low-molecular weight bioactive compounds and peptides.
Finally, 40 μL of the dialysed samples were added to the bioassay (final
dilution of 1:50).
2.3. Bioassay for measurement of GPCR-fAABs
For the identification and characterisation of GPCR-fAABs, a bioassay
was used, as described in great detail by Davideit et al. [33] and Wenzel
et al. [34] for GPCR-fAABs against the beta1-adrenoceptor, and for other
GPCR-fAABs by Wallukat et al. [30,35,36]. After contact with the
respective autoantibodies, a change in basal beating rate of spontane-
ously beating cardiomyocytes expressing GPCR was used as the
measuring signal. The receptor specificity was checked by either subse-
quent addition of specific receptor blockers, resulting in an annulation of
this effect, or by addition of corresponding receptor-epitope-competing
extracellular loop peptides. In detail: for the specification of the
β2-fAABs, the receptor antagonist ICI118.551 (0.1 μM) was used and also
neutralizing peptides corresponding to the first (HILMKMWTFGNFW-
CEFWT) or second (HWYRATHQEAINCYANETCCDFFTNQ) extracellular
loop of the human β2-adrenoceptor. The effect of the negative chrono-
tropic muscarinic M2 receptor-autoantibody (M2-fAAB) was blocked by
atropine (1 μM). Losartan (1 μM) blocked the effect of the positive
chronotropic AT1-fAAB and A779 (1 μM) blocked the effect of the
negative chronotropic MAS-fAAB. For the identification of the MAS--
fAAB, additional competing peptides corresponding to the first and sec-
ond extracellular loop of the human MAS receptor of the following
sequences: LSIDYALDYELSSGHHYTIVTL and LSGEESHSRSDCRAN,
respectively, were exploited. ETA-fAABs were identified by blocking
their negative chronotropic effects through the addition of the specific
endothelin receptor antagonist BQ123 (0.1 μM) and also competing
peptides corresponding to the first or second extracellular loop of the
receptor of the following sequences, LPINVFKL-
LAGRWPFDHNDFGVFLCKL and FEYRGEQHKTCMNATSKFME-
FYQDVKD, respectively. The nociceptin receptor antagonist J113397
(0.1 μM) was used to block the effects of the positive chronotropic
NOC-fAAB and also competing peptides corresponding to the first
(LAVCVGGLLGNCLVMYV) or second (FTLTAMSVDRYVAICHPIR-
ALDVR) extracellular loop. Addition of 1 μM urapidil or prazosin abol-
ished the positive chronotropic effect of α1-fAABs. For the loop analysis
the following competing peptides corresponding to the 1st or 2nd extra-
cellular loop of the receptor were used: LGYWAFGRVFCN and
GWRQPAPEDETICQINEEPGYVLFSAL, respectively. For all peptides 2 μL
of a stock solution of 100 μg/mL was added to 40 μL of the corresponding
GPCR-fAAB sample and incubated for 30min before the mixture was
transferred to the cells.
3. Results
Several different GPCR-fAABs were identified in the 31 sera of
recovered COVID-19 patients. All 31 investigated patients had between 2
and 7 different GPCR-fAAB (Table 1). This was a surprising unexpected
effect. In healthy controls, which are included in many studies, these
autoantibodies are only found in a small percentage [37,38]”.
Two functionally active autoantibodies, that were seen in almost all
Table 1







Symptom class Symptoms Neuro-active
fAABs
Vasoactive fAABs Neuro- and
vasocative fAABs
RAS-specific fAABs
Neuro* Cardiovasc** Neuro* Cardiovasc** Noc-fAABx β2-fAAB$ α1-fAAB& ETA-fAABþ M2-fAAB% AT1-fAAB? MAS-fAAB#
1 F 48 1 x x Fatigue, Alopecia,
Anomic aphasia
Tachycardia x x x x x x
7 F 55 2 x x Fatigue, Alopecia Tachycardia x x x x x x x
11 F 39 3 x x Fatigue, Alopecia Tachycardia x x x x x
19 F 34 4 x x Fatigue, PoTS, Tremor Tachycardia x x x x x
22 F 34 5 x x Fatigue, Alopecia Tachycardia x x x x x
29 F 49 6 x x PoTS Tachycardia x x x x x
26 M 28 7 x x PoTS Tachycardia,
Hypertension
x x x x x
30 M 55 8 x x PoTS Bradycardia x x x x
27 M 69 9 x x PoTS, Attention deficit Tachycardia x x x x x
31 M 44 10 x x Attention deficit Bradycardia x x x x
3 F 56 11 x x Fatigue, Attention deficit Tachycardia, x x x x x x
21 F 28 12 x x Attention deficit, Tremor,
Dysautonomia
Arrhythmia x x x x
18 F 53 13 x x Tremor, Attention deficit Tachycardia x x
20 M 54 14 x x Attention deficit Tachycardia,
Hypertension
x x
14 F 57 15 x x Fatigue, Anomic aphasia Arrhythmia,
Hypertension
x x x x x
23 F 50 16 x x Eczema, Alopecia Myocarditis x x x x x
28 M 65 17 x x Smell/Taste disorder. Tachycardia,
Myocarditis
x x x x x
24 F 33 18 x x Fatigue, PoTS n.a. x x x x x x
2 M 42 19 x – Fatigue, Alopecia n.a. x x x x
4 M 50 20 x – Fatigue n.a. x x x x
5 F 45 21 x – Fatigue n.a. x x x x
6 F 36 22 x – Tremor, Alopecia,
Dysautonomia
n.a. x x x x x x x
9 F 50 23 x – Fatigue n.a. x x x x x
10 F 48 24 x – Fatigue n.a. x x x x x
12 F 53 25 x – Fatigue, Attention deficit n.a. x x x x x
15 F 46 26 x – Fatigue, Alopecia,
Polyneuropathy
n.a. x x x x x
17 F 49 27 x – Fatigue, PoTS, Tremor n.a. x x
25 F 58 28 x – Attention deficit,
Neuropathy
n.a. x x x x x
13 F 26 29 x – Fatigue n.a. x x x x
8 M 71 30 – – Symptom free Symptom free x x x x x x
16 M 54 31 – – Symptom free Symptom free x x x x x
Neuro* ¼ neurological symptoms; Cardiovasc** ¼ cardiovascular symptoms, n.a. ¼ not applicable, PoTS ¼ postural orthostatic tachycardia syndrome; NOC-fAABx ¼ functionally active autoantibody against the nociceptin
receptor, β2-fAAB$ ¼ autoantibody targeting the beta2-adrenoceptor, α1-fAAB& ¼ autoantibody targeting the alpha1-adrenoceptor, ETA-fAABþ ¼ autoantibody targeting the endothelin receptor, M2-fAAB% ¼ autoantibody















Fig. 1. Loop analysis of selected
GPCR-fAAB positive samples. A: posi-
tive chronotropic GPCR-fABBs: α1-fAAB,
β2-fAAB and NOC-fAAB and B: negative
chronotropic GPCR-fABBs: ETA-1-fAAB,
MAS-fAAB samples were preincubated
with 0.2 μg of the corresponding
competing loop peptides as indicated
under Material and methods for 30 min
before the mixture was added to the
cells for the recording of the corre-
sponding GPCR-fAAB effect. In the case
of competition, the chronotropic
response was abolished, which was
achieved in four cases by the loop pep-
tides specific to the 2nd extracellular
loops. Only the α1-fAAB targeted the 1st
extracellular loop.
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adrenoceptor (β2-fAAB) and the muscarinic M2 receptor (M2-fAAB).
These fAABs induced a positive and a negative chronotropic response on
their targeted receptors, respectively.
Two other fAABs that were also present in 29 (90%) of the 31
investigated post-COVID-19 patients were directed against the angio-
tensin II AT1 receptor (fAT1-AAB) and the angiotensin 1-7 MAS receptor
(MAS-AAB). These receptors belong to the renin angiotensin system
(RAS) and cause a positive and negative chronotropic effect, respectively,
when targeted by the respective fAABs.
Post-infection hair loss (alopecia) was experienced by 8 of the
recovered patients. In sera of these patients, three additional GPCR-fAABs
were discovered: the negative chronotropic ETA-fAAB (4/8), the positive
chronotropic NOC-fAAB (5/8), and the positive chronotropic α1-AAB (3/
8). Not every alopecia patient showed all three of these GPCR-fAABs.
Instead, their occurrence varied, and a pattern is not yet detectable. As
shown in (Table 1), 2 of the 31 investigated post COVID-19 patients
developed fAABs without showing any symptoms.
In a next step it was analysed at selected ETA-1-fAAB, MAS-fAAB and
α1-fAAB, β2-fAAB and NOC-fAAB positive samples which of the extra-
cellular loops of the receptors were targeted by the respective autoanti-
bodies by addition of competing loop peptides (Fig. 1). Here it was
clearly to see that with four of the tested autoantibodies (ETA-1-fAAB,
MAS-fAAB, β2-fAAB, and NOC-fAAB) in each of the investigated cases the
second extracellular loop of the receptor was targeted by the autoanti-
body and consequently neutralized by addition of its competing loop
peptide. α1-fAAB containing samples targeted the 1st extracellular loop of
the receptor. This analysis provided additional evidence that no
nonspecific effects had influenced the outcome.
4. Discussion
The astonishing finding of this investigation is the fact that an un-
usually high number of GPCR-fAABs were detected in the serum of
recovered COVID-19 patients who mostly suffered from a variety of
different post-COVID-19 symptoms. Due to the functionality of such
GPCR-fAABs, the question of whether these GPCR-fAABs may play a role
in the development of post-COVID-19 symptoms is raised.
A continuing fatigue-like symptom, persisting long after virus follow-
up tests are negative, was a frequently reported impairment in patients of
this study (17/31), and other studies [1]. For patients suffering from a
classical coronavirus-independent fatigue syndrome, the occurrence of
β2-fAABs, M2-fAABs and, in some cases, also ETA-fAABs has already been
reported before [39]. Here, with this post-COVID-19 study, almost all
investigated sera contained β2-fAABs and M2-fAABs. The combination of
β2-fAABs and M2-fAABs have also been identified in sera of patients
suffering from PoTS and dysautonomia [40], both of which are condi-
tions now observed in post-COVID-19 patients (7/31 and 2/31,4
respectively, not overlapping). Furthermore, this combination of
β2-fAABs with M2-fAABs had also been identified before by our group, in
patients with complex regional pain syndrome (CRPS) [41], in patients
suffering from narcolepsy type 1, here additionally with the NOC-fAAB in
9 of 10 cases [36] and in patients with small fibre diseases.
Two of the identified GPCR-fAABs, observed in over 90% of the
investigated COVID-19 patient sera (29/31), were directed against re-
ceptors of RAS, namely the angiotensin II AT1 receptor and the angio-
tensin (1–7) MAS receptor. These vasoactive AT1-fAABs had been
identified before in patients with malignant hypertension, therapy-
resistant hypertension, preeclampsia, and kidney diseases [42–44].
Moreover, Dragun et al. [44] showed that AT1-fAABs induced the
rejection of kidneys in a subgroup of patients that underwent kidney
transplantation. The authors also showed that the transfer of human
AT1-fAABs to kidney transplanted rats caused the occlusion of the kidney
arteries in the recipients.
Given the evidence described above, it may be that vasoactive pro-
cesses, caused by the occurrence of AT1-fAABs and MAS-fAABs, might
also be involved in the pathogenesis of post-COVID-19 symptoms.
However, it is highly unlikely that the pathophysiological effects are
caused by the fAABs alone. For example, Lukitsch and co-workers [45]
already showed that the addition of the human AT1-fAABs to isolated
kidney arteries induced a contraction of these arteries, but only in
ischemic arteries and in arteries that were taken from kidney trans-
planted rats. Arteries obtained from healthy rats did not respond to
AT1-fAABs, even though they reacted to their natural agonist, angio-
tensin II (which confirmed that the receptors were intact). Taken
together, these data demonstrated that the AT1-fAABs did not act alone
but needed ischaemic or inflammatory cofactors to have full effect. With
respect to the COVID-19 situation, this is of course an absolutely obvious
situation. Thrombo-inflammatory factors which even may become pre-
dictive markers for COVID-19 complications have been described by
Cremer et al. [46]. Other immune biomarkers, as taken together by
Fouladseresht et al. [47] have also been reported.
To date, the evidence suggests that a combination of ischaemic or
inflammatory cofactors and autoantibodies can act to maintain a cardiac
inflammatory process. Specifically, it has been shown that AT1-fAABs
and α1-fAABs can influence the maturation and degranulation of cardiac
mast cells [48], suggesting that they can contribute to inflammation.
It has also already been reported that COVID-19 induces an imbalance
of RAS through viral-occupation of the angiotensin-converting enzyme 2
(ACE2) receptors, which reduces the generation of protective-peptides
angiotensin-(1–7) and (1–9). This subsequently decreases the stimula-
tion the MAS- and angiotensin II ATR2-receptors, and is accompanied by
an overstimulation of the AT1-receptors due to reduced degradation of
angiotensin II by ACE2 [49]. Therefore, Steckelings and Sumners [49]
recently suggested that ATR2 receptor agonists could be used to treat
COVID-19-induced disorders of various organ systems.
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over 90% of the symptomatic patients examined. Autoantibodies against
this receptor have been observed before in a cancer patient after
chemotherapy [50] and in patients with multiple sclerosis (MS) (un-
published results). In MS patients we observed the combination of
MAS-fAABs with α1-fAABs. In this context, it is interesting to see that in
several case reports it was shown that COVID-19 patients can develop
neurological complications like transverse myelitis [2] and
Guillain-Barre syndrome [5,7]. Whether the MAS-fAABs observed in this
COVID-19 study is involved in the development of the reported neuro-
logical symptoms should be clarified in further investigations.
Furthermore, our data showed that 2 of the patients with a mild
COVID-19 infection developed fAABs but not the symptoms as seen in the
other recovered COVID-19 patients. We assume that in both of these
patients adaption processes might have prevented the binding of fAABs to
the receptor or the receptors are not available for the fAABs as described
by Lukitsch and co-worker for angiotensin II AT1 fAAB before [45].
We strongly assume that the GPCR-fAABs play an important role in
the development and maintenance of post-COVID symptoms. These
GPCR-fAABs persistently stimulate their corresponding receptors and the
normal, physiological, cell-protective desensitisation of the receptors is
inhibited by the fAABs themselves [51].
It has already been shown in other diseases, such as idiopathic dilated
cardiomyopathy (here it is the autoantibody targeting the beta1-
adrenoceotor), that GPCR-fAABs play a significant role in the pathogen-
esis of the disease [31]. Additionally, the removal of these fAABs by
immunoadsorption led to an improvement in cardiac function and to a
significant increase in survival rate [52,53]. A similar beneficial thera-
peutic effect of the removal of GPCR-fAABs has also been observed in
β2-fAAB positive, therapy-refractory, open-angle glaucoma patients.
Here, the removal of the fAABs by immunoadsorption resulted in a
reduction of the ocular pressure [54].
With respect to post-COVID-19 symptoms, Masuccio et al. reported a
patient who was suffering from post-infection acute motor axonal neu-
ropathy and myelitis. The patient tested positive for the ganglioside anti-
GD1b IgM autoantibody, and a partial recovery was achieved through
plasma exchange combined with subsequent immunoglobulin substitu-
tion [7].
The Sars-CoV-2 spike protein is a potential epitopic target for
biomimicry-induced autoimmunological processes [25]. Therefore, we
feel it will be extremely important to investigate whether GPCR-fAABs
will also become detectable after immunisation by vaccination against
the virus.
5. Conclusion
Our results indicated that all 29 investigated symptomatic post-
COVID-19 patients developed fAABs directed against different GPCRs,
known to be able to disturb the balance of neuronal and vascular pro-
cesses. Most of these patients developed an antibody pattern consisting of
β2-fAABs, M2-fAABs, AT1-fAABs, and MAS-fAABs. These agonistic fAABs
activate their corresponding receptors like classical agonists. The
observed specific GPCR-fAAB pattern has been observed before in several
neurological and cardiac disorders and might also support the develop-
ment of neurological and/or cardiovascular symptoms after COVID-19
recovery. These results provide valuable clues that are worth pursuing
and investigating further.
6. Limitations of the study
Amajor limitation of this study is that it is only a snapshot. Therefore,
the causal relationship between the presence of GPCR-fAAB and the
disease cannot be shown. In order to be able to identify causal relation-
ships, samples from former COVID patients must be systematically
collected over a longer period of time for GPCR-fAAB detection. After-
wards the data have to be retrospectively assigned to recovering and non-5
recovering Long-COVID-19 patients.
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